Episode 52 -The Collective Lie in Ketamine Therapy (Part 1): Why the Experience Isn't the Treatment

Written By Kimberly Ko
Episode 52 podcast cover featuring Charles Miller discussing the collective lie in ketamine therapy Part 1 with headshot

Charles Miller challenges ketamine therapy's focus on psychedelic experiences, arguing that neuroplasticity science shows we're emphasizing the wrong mechanisms and reducing treatment success rates.

Listen on Apple Podcast
Listen on Spotify
Listen on Overcast

In this first part of what became a two-part conversation, we sat down with anesthesia provider Charles Miller from Scenic City Neurotherapy for a discussion that challenged so many assumptions about ketamine therapy.

Charles presents what he calls the "collective lie" in ketamine therapy - the argument that the obsession with psychedelic experiences and mystical insights for a growing segment of providers in our industry is not just misguided, but actually making our patients worse. 

He walks through the neurobiological evidence showing that the real therapeutic action happens days after treatment during the neuroplasticity window, not during those profound moments when patients feel like they're talking to God or having life-changing realizations.

You'll hear Charles critique the research methodologies that seem to support ketamine-assisted psychotherapy, explaining why group averages can mask poor individual outcomes and why the frequently cited KAP studies may actually show lower success rates than standard ketamine protocols. He also shares refreshingly honest advice about starting a clinic - including his decision to open with folding chairs rather than go into debt for impressive furniture.

We're also trying something new with this episode: audio sidebars. As we talk, we’ll pause to provide additional context about complex concepts like psychoplastogens, research study limitations, and the cutting-edge science behind separating therapeutic effects from psychedelic experiences. Think of these as educational moments designed to help you fully understand and enjoy the episode.

This conversation will make you question whether the approaches many of us have been using actually serve our patients - or if we've been chasing the wrong mechanisms entirely.

What You'll Learn in This Episode:

  • Charles's entrepreneurial journey - How he started Scenic City Neurotherapy with minimal capital and his advice for keeping overhead low during startup

  • The "collective lie" concept - Why Charles believes the field's emphasis on ketamine experiences actually reduces treatment success rates

  • Neuroplasticity mechanisms - Detailed explanation of the NMDA-glutamate-BDNF pathway and why the therapeutic window occurs after, not during, ketamine administration

  • Psychoplastogens vs psychedelics - Understanding David E. Olson's groundbreaking research on compounds that promote neuroplasticity without hallucinogenic effects

  • Research methodology critique - Analysis of popular KAP studies and why methodological flaws may be masking poor individual patient outcomes

  • Evidence-based positioning - How to counter the "ketamine is just anesthesia" criticism with solid neurobiological science

  • Experience vs neuroplasticity - Why Charles argues that focusing on insights and visions during treatment may be counterproductive

Key Takeaways:

  • Ketamine may function primarily as a psychoplastogen rather than a classic psychedelic, blocking NMDA receptors to trigger neuroplasticity cascades instead of flooding serotonin receptors like traditional psychedelics

  • The therapeutic neuroplasticity window occur days to weeks after ketamine administration, when BDNF-driven synaptic remodeling takes place, not necessarily during the acute dissociative experience

  • Research comparing ketamine-assisted psychotherapy to standard protocols could show mixed results, with some studies reporting lower individual response rates despite promising group averages

  • Providers who overfocus on experiential components during treatment may inadvertently create performance pressure that could reduce patient outcomes and increase perceived treatment failure rates

  • Startup ketamine clinics might benefit from beginning embarrassingly small with minimal overhead, focusing resources on essential clinical equipment rather than impressive lobbies or furniture

  • David E. Olson's psychoplastogen research suggests that neuroplastic benefits might be separable from psychedelic experiences, supporting approaches that prioritize physiological mechanisms over experiential components

Listen to the episode on Apple Podcasts, Spotify, Overcast, or on your favorite podcast platform. Watch the discussion on YouTube here.

Episode 52 show notes:

  • 00:00:00 - Teaser: When Patients Feel They Failed

  • 00:00:17 - Introduction and Episode Setup

  • 00:02:06 - Charles's Journey into Ketamine Therapy

  • 00:04:30 - The Entrepreneurial Leap

  • 00:06:00 - Startup Advice: Think Embarrassingly Small

  • 00:08:30 - Evolution of the Ketamine Field

  • 00:10:00 - The "Collective Lie" Concept Introduction

  • 00:12:30 - Neurobiological Mechanisms

  • 00:16:30 - Psychoplastogens vs. Psychedelics

  • 00:24:00 - David E. Olson's Revolutionary Research

  • 00:27:27 - Audio Sidebar: Psychoplastogens & David E. Olson

  • 00:30:00 - Research Critique: KAP Study vs Real-World IV Ketamine Data

  • 00:34:27 - Episode Wrap-up

Thanks for Listening

Professional Education Disclaimer: This content is intended exclusively for licensed healthcare professionals and should not be used by patients for self-treatment or self-education. The information presented reflects individual provider experiences and should not replace clinical judgment, professional training, or comprehensive research. Healthcare providers must conduct their own due diligence, consult current literature, and evaluate treatment approaches within their specific practice context and regulatory environment. This educational content does not constitute medical advice for specific patients or clinical situations - treatment decisions should always be based on individual patient assessment and adherence to professional medical standards.

Frequently Asked Questions

What does Charles mean by "the collective lie" in ketamine therapy? 

Charles argues that the field has collectively embraced the misconception that a large part of ketamine's therapeutic effects depend on the psychedelic experience itself - the visions, insights, and mystical feelings patients have during treatment. He contends this focus on experiential components may actually reduce treatment success rates by creating performance pressure and misallocating attention away from the neuroplasticity mechanisms that occur days after treatment when BDNF rebuilds synaptic connections. Further explore what he wrote on this topic in "The collective lie in ketamine therapy: a call to realign clinical practice with neurobiology" in Front. Psychiatry, 21 September 2025, Sec. Psychopharmacology.

What's the difference between psychoplastogens and psychedelics that Charles discusses? 

Psychoplastogens are compounds that promote neuroplasticity, which may include but isn't limited to psychedelics. David E. Olson's research at UC Davis demonstrates that you can potentially design compounds retaining neuroplastic benefits while eliminating hallucinogenic experiences. Classical psychedelics like psilocybin flood serotonin receptors and create plasticity simultaneously, while ketamine blocks NMDA receptors to trigger plasticity cascades without the serotonergic mechanisms that define traditional psychedelics.

Are the research studies supporting KAP actually flawed as suggested in the episode?

Charles critiques specific methodological limitations in some KAP research, particularly the Dore 2019 study which reported group averages rather than individual response rates and used variable protocols. When compared to large real-world datasets like the McInnes study showing 53.6% individual response rates with standard IV ketamine, some KAP research may show lower individual success rates despite promising group averages. Providers should evaluate research methodology carefully, focusing on individual patient outcomes rather than group statistics.

How can I implement Charles's neuroplasticity-focused approach in my practice? 

You might consider emphasizing patient education about the BDNF-driven neuroplasticity window that occurs post-treatment rather than focusing on achieving specific experiences during infusion. This could include explaining that therapeutic change happens through subsequent lifestyle practices, therapy work, and sleep optimization when the brain rebuilds synaptic connections. The approach may reduce patient performance anxiety while maintaining realistic expectations about when therapeutic benefits typically emerge. For more information about Charles's MSKIT protocol and approach, visit www.sceniccityneurotherapy.com.

 
Kimberly Ko
Next

Episode 51 - The 4 Ketamine Clinic Business Stages: How to Know Where You Are and What to Do Next